-
Functional Areas
- Audit and Investigations
-
Capacity development and transition, strengthening systems for health
- A Strategic Approach to Capacity Development
- Capacity Development and Transition - Lessons Learned
- Capacity development and Transition Planning Process
- Capacity Development and Transition
- Capacity Development Objectives and Transition Milestones
- Capacity Development Results - Evidence From Country Experiences
- Functional Capacities
- Interim Principal Recipient of Global Fund Grants
- Legal and Policy Enabling Environment
- Overview
- Resilience and Sustainability
- Transition
-
Financial Management
- CCM Funding
- Grant Closure
- Grant Implementation
- Grant-Making and Signing
- Grant Reporting
- Import duties and VAT / sales tax
- Overview
- Sub-recipient Management
-
Grant closure
- Overview
-
Steps of Grant Closure Process
- 1. Global Fund Notification Letter 'Guidance on Grant Closure'
- 2. Preparation and Submission of Grant Close-Out Plan and Budget
- 3. Global Fund Approval of Grant Close-Out Plan
- 4. Implementation of Close-Out Plan and Completion of Final Global Fund Requirements (Grant Closure Period)
- 5. Operational Closure of Project
- 6. Financial Closure of Project
- 7. Documentation of Grant Closure with Global Fund Grant Closure Letter
- Terminology and Scenarios for Grant Closure Process
- Human resources
- Human rights, key populations and gender
-
Legal Framework
- Agreements with Sub-recipients
- Agreements with Sub-sub-recipients
- Amending Legal Agreements
- Implementation Letters and Performance Letters
- Language of the Grant Agreement and other Legal Instruments
- Legal Framework for Other UNDP Support Roles
- Other Legal and Implementation Considerations
- Overview
- Project Document
- Signing Legal Agreements and Requests for Disbursement
-
The Grant Agreement
- Grant Confirmation: Conditions Precedent (CP)
- Grant Confirmation: Conditions
- Grant Confirmation: Face Sheet
- Grant Confirmation: Schedule 1, Integrated Grant Description
- Grant Confirmation: Schedule 1, Performance Framework
- Grant Confirmation: Schedule 1, Summary Budget
- Grant Confirmation: Special Conditions (SCs)
- Grant Confirmation
- UNDP-Global Fund Grant Regulations
-
Monitoring and Evaluation
- Differentiation Approach
- Monitoring and Evaluation Components of Funding Request
- M&E Components of Grant Implementation
- Monitoring and Evaluation Components of Grant Making
- Overview
- Principal Recipient Start-Up
-
Health Product Management
- Compliance with the Global Fund requirements
- Distribution
- Inspection and Receipt
- International freight, transit requirements and use of INCOTERMS
- Inventory Management
- Overview - Health Product Management
- Pharmacovigilance
- Product Selection
- Quality monitoring of health products
- Quantification and Forecasting
- Rational use
- Risk Management for PSM of health products
-
Sourcing and regulatory aspects
- Development of List of Health Products
- Development of the Health Procurement Action Plan (HPAP)
- Global Health Procurement Center (GHPC)
- Guidance on donations of health products
- Health Procurement Architecture
- Local Procurement of health products
- Other Elements of the UNDP Procurement Architecture
- Procurement of non-pharmaceutical Health Products
- Procurement of Pharmaceutical Products
- Submission of GHPC CO Procurement Request Form
- Storage
- Supply Planning of Health Products
- UNDP Health PSM Roster
- Waste management
- Grant Reporting
-
Risk Management
- Introduction to Risk Management
- Overview
- Risk management in crisis settings
-
Risk Management in the Global Fund
- Additional Safeguard Policy
- Challenging Operating Environment (COE) Policy
- Global Fund Review of Risk Management During Grant Implementation
- Global Fund Risk Management Framework
- Global Fund Risk Management Requirements During Funding Request
- Global Fund Risk Management Requirements for PRs
- Local Fund Agent
- Risk management in UNDP
- Risk Management in UNDP-managed Global Fund projects
- UNDP Risk Management Process
- Sub-Recipient Management
Quality Control (QC) activities
As per the UNDP QA Policy, products purchased through UNDP must be tested according to a randomized sampling plan, which is based on a risk assessment by product category and by product. The GHPC QAS Team has issued guidance for Country Offices outlining 1) how to prepare a multi-year QC Plan including a template, and 2) how to prepare an annual Sampling Plan including a template and a calculation tool and instructions on how to use the tool.
The annual sampling plan should include the number of batches to be tested based on the annual procurement plan. Both random and targeted risk-based sampling is recommended at different points across the supply chain. The selection of batches to be tested should follow the recommendations in section VII of the Guidance for UNDP Country Offices on Health Products Quality Assurance in the Supply Chain.
The PR must implement the annual plan and must maintain a record of the test results. The test results must also be shared with the GHPC QAS team.
For FPPs and Diagnostics approved by the WHO ERP and procured with Global Fund grant resources, the Global Fund Secretariat is responsible for organizing and paying for the quality control of these products prior to their shipment. UNDP COs are responsible for notifying the Global Fund Secretariat of their intent to purchase such products – using the following forms pharmaceuticals, additional Order of ERP Pharmaceutical Products, and diagnostics – and must receive a “no objection letter” (NOL) before confirming the purchase order. The NOL must be provided to the GHPC HPS and QAS teams before the PO can be issued.
Once the products are ready for sampling, the manufacturer informs the Global Fund who organizes the sampling and testing by a third-party laboratory contracted by the Global Fund. Upon receipt of a successful test results, the Global Fund will issue the final letter, including the test report, to the PR and the manufacturer, authorizing the product shipment. This letter must also be provided to the GHPC QAS team for their records.
For pharmaceuticals, other than ERP products, UNDP has established LTAs with Quality Control laboratories that are WHO prequalified for the provision of sampling and testing of pharmaceuticals. The existing LTAs expired at the end of 2023 and are being re-tendered. A link to the new LTAs and corresponding standard operating procedures (SOPs) will be shared later in 2024. LTAs for pre-shipment inspection and for QC laboratories for sampling and testing of other product categories are being established and should be available during semester 2 of 2024.
Additional guidance to support this area of work are also available through resources listed below:
Loading resources
